🍽️ loratadine,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Allergic Rhinitis: Loratadine is primarily used to treat allergic rhinitis, commonly known as hay fever. It can help relieve symptoms such as sneezing, runny or itchy nose, and itchy or watery eyes.

  2. Urticaria (Hives): Loratadine is effective in reducing the symptoms of urticaria, including itching, redness, and swelling of the skin.

  3. Allergic Conjunctivitis: Loratadine may provide relief from symptoms of allergic conjunctivitis, such as redness, itching, and watering of the eyes.

  4. Allergic Dermatitis: Loratadine can help alleviate itching and other symptoms associated with allergic dermatitis or skin allergies.

  5. Pruritus (Itching): Loratadine may be prescribed to relieve itching associated with various allergic reactions, insect bites, or other skin conditions.

  6. Nasal Congestion: While loratadine primarily targets symptoms like sneezing and runny nose, it may have limited effectiveness in relieving nasal congestion compared to other medications like pseudoephedrine.

  7. Chronic Idiopathic Urticaria (CIU): Loratadine is also used in the treatment of chronic idiopathic urticaria, a condition characterized by recurrent hives with no identifiable cause.

  8. Seasonal Allergies: Loratadine is commonly used to alleviate symptoms of seasonal allergies, such as those caused by pollen, grass, or mold spores.

  9. Non-Allergic Rhinitis: Loratadine may also be used to alleviate symptoms of non-allergic rhinitis, although it may be less effective compared to antihistamines specifically targeting this condition.

  10. Children's Allergies: Loratadine formulations specifically designed for children are available and may be prescribed to alleviate allergy symptoms in pediatric patients.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

Data Contradictions β€” Limits of Certainity

Impacted of loratadine,(prescription) On Probiotics

Rank Probiotic Impact

Bacteria Impacted by loratadine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Klebsiella genus Decreases 📓 Source Study Pathogen
Klebsiella/Raoultella group no rank Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
unclassified Klebsiella no rank Decreases 👶 Source Study
Eggerthellales order Decreases ⚗️ Source Study
Klebsiella pneumoniae species Decreases 📓 Source Study H00301 Klebsiella infection, Pneumonia
Asaccharospora irregularis species Decreases ⚗️ Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Klebsiella aerogenes species Decreases 👶 Source Study
Klebsiella africana species Decreases 👶 Source Study
Klebsiella granulomatis species Decreases 👶 Source Study
Klebsiella grimontii species Decreases 👶 Source Study
Klebsiella huaxiensis species Decreases 👶 Source Study H00301 Klebsiella infection
Klebsiella michiganensis species Decreases 👶 Source Study
Klebsiella oxytoca species Decreases 👶 Source Study
Klebsiella pasteurii species Decreases 👶 Source Study
Klebsiella quasipneumoniae species Decreases 👶 Source Study H00301 Klebsiella infection
Klebsiella quasivariicola species Decreases 👶 Source Study H00301 Klebsiella infection
Klebsiella variicola species Decreases 👶 Source Study
Lactonifactor longoviformis species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Anaerosporobacter mobilis species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Klebsiella pneumoniae JM45 strain Decreases 👶 Source Study
Klebsiella pneumoniae KCTC 2242 strain Decreases 👶 Source Study
Klebsiella pneumoniae KP-1 strain Decreases 👶 Source Study
Klebsiella pneumoniae subsp. pneumoniae subspecies Decreases 👶 Source Study H00301 Klebsiella infection
Klebsiella pneumoniae subsp. rhinoscleromatis subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of loratadine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Allergy to milk products 0.5 0.5
Ankylosing spondylitis 0.3 0.3
Antiphospholipid syndrome (APS) 0.5 0.5
Atrial fibrillation 0.5 0.5
Autism 0.3 0.5 -0.67
Biofilm 0.3 0.3
Bipolar Disorder 0.5 0.5
Carcinoma 0.5 0.5
Chronic Fatigue Syndrome 0.6 0.6
Coagulation / Micro clot triggering bacteria 0.3 0.3
Colorectal Cancer 0.5 0.5
COVID-19 0.2 -0.2
Crohn's Disease 0.5 0.5 0
deep vein thrombosis 0.3 0.3
Depression 0.6 0.6
Functional constipation / chronic idiopathic constipation 0.5 0.5
Generalized anxiety disorder 0.2 0.2
Hashimoto's thyroiditis 0.3 0.5 -0.67
High Histamine/low DAO 1 1
hypersomnia 0.5 0.5
hypertension (High Blood Pressure 0.5 0.5 0
Inflammatory Bowel Disease 0.5 0.5
Irritable Bowel Syndrome 0.5 0.5 0
Liver Cirrhosis 0.5 0.5
Long COVID 0.5 -0.5
Mast Cell Issues / mastitis 0.5 0.5
ME/CFS without IBS 0.1 0.1
Metabolic Syndrome 0.8 0.8
Mood Disorders 0.6 0.6
Obesity 0.8 0.3 1.67
obsessive-compulsive disorder 0.8 0.8
Parkinson's Disease 1 1
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.5 0.5
Schizophrenia 0.5 0.5
Small Intestinal Bacterial Overgrowth (SIBO) 0.8 0.8
Systemic Lupus Erythematosus 0.5 0.5
Type 2 Diabetes 0.8 0.8
Ulcerative colitis 0.5 0.5

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results. < p > Explanations / Info / Descriptions are influenced by < a href = "/home/sources" target = "_blank" > Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction. < p style = "font-size" .4em"> Copyright 2016 - 2024 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA < br /> Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. < br />< em > Caveat emptor: Analysis and suggestions are based on modelling(and thus < i > infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions / Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [44.213.60 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [44.213.60 ]